cropped color_logo_with_background.png

Clinical Trial Finder

INtraoperative photoDYnamic Therapy of GliOblastoma

Study Purpose

The study pilot evaluate the feasibility of a "5-ALA- PpIX (protoporhyrin IX) mediated per-PDT protocol" in patients with glioblastoma accessible for complete surgical removal of contrast. This treatment will be carried out in addition to the current reference treatment of glioblastoma: maximum resection surgery followed by radiochemotherapy according to the protocol Stupp

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

 No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

 Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

1. Patient male or female ≥18 years. 2. General status (WHO) of Performance status 0, 1 or 2. 3. Probable glioblastoma according to clinical and radiological criteria, 4. whose surgical indication was given in Multidisciplinary consultation meeting (RCP) of neurooncology, 5. Decision to treat the patient as part of the Clinical trial also taken in neuro-oncology RCP ("Multidisciplinary consultation meeting") 6. Patient operable on the basis of absence of cardiopulmonary disease history; a complete medical check-up sufficient to insure a post-operative state with normal daily life. 7. Clinical neuro-oncological monitoring and long-term MRI scheduled at the hospital CHRU of Lille, center of reference of the region. 8. Patient able to understand and sign voluntarily Informed consent. 9. Patient able to adhere to the visit's calendar of the study and other imperatives of the protocol. 10. Women of child-bearing potential should benefit of an effective contraception. 11. For patients receiving hepatotoxic therapy in the long term, this treatment must be suspended during the 24h after taking 5-ALA. 12. Patient assigned to an heath insurance.

Exclusion Criteria:

1. Contraindications to 5-ALA (Gliolan®) and to per-operative PhotoDynamic Therapy "perPDT": 2. Contraindications to 5-ALA.
  • - Porphyria.
  • - Taking photosensitizer treatment.
  • - Severe renal or hepatic impairment.
  • - Bilirubin> 1.5 x maximum level, Alkaline Phosphatases and transaminases (ASAT)> 2.5 x Maximum.
rates.
  • - Creatinine clearance <30 mL / min; - Non-compliance with the rules of prevention of the transient risk of cutaneous photosensitization.
3. Contraindications to surgery. 4. Contraindications to magnetic resonance imaging (MRI) 5. Treatment with an experimental drug within 30 Days prior to the start of the study. 6. Clinical follow-up impossible to perform for psychological, familial, social or geographical reasons, 7. Legal incapacity (persons deprived of their liberty or Guardianship or guardianship), 8. Pregnant or nursing women. 9. Refusal to participate or sign the consent of the study. 10. Soy allergy

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

 NCT03048240
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

 N/A
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

 University Hospital, Lille
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

 Nicolas Reyns, MD, PhD
Principal Investigator Affiliation University Hospital, Lille
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

 Other
Overall Status Completed
Countries France
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

 Glioblastoma
Arms & Interventions

Arms

Experimental: "perPDT"

Single arm : per-operative PhotoDynamic Therapy (perPDT) during the surgery of Glioblastoma excision.

Interventions

Device: - "perPDT"

The protocol requires the realization of specific procedures in addition to the usual care. The per-operative photodynamic therapy ("perPDT") added to surgery for glioblastoma excision. The patient will receive 5-ALA (5- alanine ,GLIOLAN drinkable) 4h before surgery + lighting of the tumor bed by a light source (laser) at the end of resection (Prolonged surgery of 45 minutes).

Drug: - GLIOLAN

patient will receive 5-ALA (5- alanine ,GLIOLAN drinkable) 4h before surgery

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Hôpital Roger Salengro, CHRU, Lille, France

Status

Address

Hôpital Roger Salengro, CHRU

Lille, ,

Powered By